ZNF385B expression associates with survival in triple negative breast cancer.

Shahan Mamoor, MS¹

¹shahanmamoor@gmail.com

East Islip, NY USA

We mined published microarray data (1) to understand the most significant gene expression differences in the tumors of triple negative breast cancer patients based on survival following treatment: dead or alive. We observed significant transcriptome-wide differential expression of zinc finger protein 385B, encoded by ZNF385B when comparing the primary tumors of triple negative breast cancer patients dead or alive. Importantly, ZNF385B expression was correlated with recurrence-free survival in basal subtype breast cancer, a molecular subtype sharing significant overlap with triple negative breast cancer. ZNF385B may be of relevance as a biomarker or as a molecule of interest in understanding the etiology or progression of triple negative breast cancer.

Keywords: triple negative breast cancer, TNBC, systems biology of breast cancer, targeted therapeutics in breast cancer, ZNF385B, zinc finger protein 385B.

Triple negative breast cancer is defined by lack of expression of the receptors for the hormones progesterone and estrogen (PR negative and ER negative), as well as for the human epidermal growth factor receptor 2 (HER2 negative) (2, 3). Though not completely identical, triple negative breast cancer shares significant overlap with the basal or basal-like molecular subtype of human breast cancer (3). TNBC is more frequently diagnosed in women of African descent (black women) for reasons not understood, and their disease course is similarly more aggressive than in white women with triple negative breast cancer (2, 3). To understand the transcriptional biology of triple negative breast cancer in an unbiased fashion and at the systems level, we mined published microarray data paired with patient survival data (1), performing comparative transcriptome analysis based on survival at time of data collection: dead or alive. We present here a finding from the results of this analysis.

Methods

We used dataset GSE142102 (1) for this differential gene expression analysis in conjunction with GEO2R. GSE142102 was generated using Affymetrix Human Gene 2.1 ST Array technology; in this analysis, we used data from $n=87$ tumors from TNBC patients that were dead at time of analysis and $n=123$ tumors from TNBC patients that were alive at time of analysis. The Benjamini and Hochberg method of p -value adjustment was used for ranking of differential expression but raw p -values were used to assess statistical significance of global differential expression. Log-transformation of data was auto-detected, and the NCBI generated category of platform annotation was used. A statistical test was performed to evaluate whether ZNF385B expression was significantly different between the primary tumors of TNBC patients that were dead or alive using a two-tailed t-test. For Kaplan-Meier survival analysis, we used the Kaplan-Meier plotter tool (4) for correlation of ZNF385B mRNA expression levels with recurrence-free survival (RFS) in $n=442$ patients with basal subtype breast cancer.

Results

We performed comparative transcriptome analysis using published microarray data (1) to understand in an unbiased fashion the most significant gene expression differences in the primary tumors of patients with triple negative breast cancer based on survival outcomes.

ZNF385B is differentially expressed in triple negative breast cancer and negatively correlates with survival.

When comparing primary tumors of 87 live patients with triple negative breast cancer with that of 123 dead TNBC patients we identified zinc finger protein 385B, *ZNF385B*, as among the most significant transcriptional differences based on survival in human triple negative breast cancer. When ranking each of the transcripts whose expression was measured by microarray based on significance of difference in expression between the tumors of patients dead and alive, ZNF385B ranked 131 out of 53617 total transcripts, equivalent to 99.8% differential expression (Chart 1). ZNF385B differential expression in the tumors of patients based on survival outcomes was statistically significant (Figure 1; $p=0.00323364$).

ZNF385B is expressed at significantly lower levels in the breast tumors of TNBC patients when comparing based on survival.

We obtained exact mRNA expression levels for ZNF385B from breast tumors of TNBC patients dead and alive to understand the magnitude and direction of ZNF385B expression change based on

1 survival outcomes. ZNF385B was expressed at lower levels in tumors of TNBC patients alive as
2 compared to that of TNBC patients dead (Figure 1). Decreased expression of ZNF385B in primary breast
3 tumors was statistically significant (Figure 1: $p=0.0029$). ZNF385B was expressed at 0.21 ± 0.99 arbitrary
4 units (AU) in the primary tumors of TNBC patients alive, while it was expressed at -0.20 ± 0.94 AU in
the primary tumors of TNBC patients dead.

5 ZNF385B expression correlates with recurrence-free survival in basal subtype human breast cancer.

6 We referenced a bioinformatics tool containing Kaplan-Meier survival data of human breast cancer
7 patients to understand more thoroughly whether a relationship existed between ZNF385B primary tumor
8 expression and patient survival in human breast cancer. We found that ZNF385B expression was
9 correlated with recurrence-free survival in patients with basal or basal-like human breast cancer, a breast
10 cancer molecular subtype which shares significant overlap with triple negative breast cancer (Figure 2; log
11 rank p -value: 0.00092 for recurrence-free survival, hazard ratio: 0.59 (0.43-0.81) (Fig. 2)). ZNF385B
mRNA levels were a positive prognostic indicator in basal subtype breast cancer patients. Median RFS
was 17.76 months for basal subtype patients with low tumor expression of ZNF385B as compared to
30.42 months for basal subtype patients with high tumor expression of ZNF385B.

12 Thus, we found through unbiased comparative transcriptome analysis that ZNF385B was among
13 the genes whose expression was most significantly different in the primary tumors of triple negative breast
14 cancer patients alive when compared to that of TNBC patients dead, that ZNF385B was expressed at
15 significantly lower levels in the primary tumors of TNBC patients alive as compared to TNBC patients
dead, and that ZNF385B expression was positively correlated with recurrence-free survival in the basal or
basal-like molecular subtype.

16 **Discussion**

17 It is not understood why women of African descent (black women) are diagnosed with triple
18 negative breast cancer more frequently than white women, and why this disease is more aggressive in
19 black women. ZNF385B is expressed in Burkitt lymphoma and in germinal center B-cells where it
20 influences apoptotic cell death (5, 6). ZNF385B may be of relevance as a biomarker in identifying patients
21 who are more likely to survive, perhaps as part of a panel of genes used for prognostic stratification, and
the molecule itself may be important to the biology of triple negative breast cancer etiology or more likely
its progression. Blind systems-level analyses, like this, can help shed light on the fundamental molecular
characteristics of a disease whose racial propensities demand further explanation.

References

1. Purrington, K.S., Knight III, J., Dyson, G., Ali-Fehmi, R., Schwartz, A.G., Boerner, J.L. and Bandyopadhyay, S., 2020. CLCA2 expression is associated with survival among African American women with triple negative breast cancer. *PloS one*, 15(4), p.e0231712.
2. Foulkes, W.D., Smith, I.E. and Reis-Filho, J.S., 2010. Triple-negative breast cancer. *New England journal of medicine*, 363(20), pp.1938-1948.
3. Dietze, E.C., Sistrunk, C., Miranda-Carboni, G., O'regan, R. and Seewaldt, V.L., 2015. Triple-negative breast cancer in African-American women: disparities versus biology. *Nature Reviews Cancer*, 15(4), pp.248-254.
4. Györfy, B., Lanczky, A., Eklund, A.C., Denkert, C., Budczies, J., Li, Q. and Szallasi, Z., 2010. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. *Breast cancer research and treatment*, 123(3), pp.725-731.
5. Iijima, K., Yamada, H., Miharu, M., Imadome, K.I., Miyagawa, Y., Akimoto, S., Kobayashi, K., Okita, H., Nakazawa, A., Fujiwara, S. and Fujimoto, J., 2012. ZNF 385 B is characteristically expressed in germinal center B cells and involved in B-cell apoptosis. *European journal of immunology*, 42(12), pp.3405-3415.
6. Iijima, K., Yamada, H., Miharu, M., Nakazawa, A., Fujimoto, J., Kobayashi, K., Okita, H. and Kiyokawa, N., 2011. Burkitt Lymphoma Specific Zinc Finger Protein ZNF385B Is Involved in Regulation of B Cell Apoptosis.

Rank: 131
Probe ID: 16906031
p-value: 0.00323364
t: 2.944609
B: -3.33
Gene: ZNF385B
Gene name: zinc finger protein 385B

Chart 1: ZNF385B is differentially expressed at the transcriptome-level when comparing the primary tumors of TNBC patients dead and alive.

Rank of differential expression, probe ID, *p*-value of global differential expression, *t*, a moderated *t*-statistic, *B*, the log-odds of differential expression between the groups compared, gene and gene name are listed in this chart.

Figure 1: ZNF385B is expressed at significantly lower levels in the primary tumors of TNBC patients alive as compared to the primary tumors of TNBC patients dead.

The mRNA expression level of ZNF385B in the primary tumors of TNBC patients dead (left) and in primary tumors of TNBC patients alive (right) is graphically depicted with the result of a statistical test evaluating significance of difference in ZNF385B expression between the primary tumors of TNBC patients dead and alive, a p -value, listed here: $p=0.0036$.

Figure 2: ZNF385B expression correlates with recurrence-free survival in basal subtype human breast cancer.

Depicted in this Kaplan-Meier plot is the probability of recurrence-free survival (RFS) for $n=442$ breast cancer patients of basal subtype, based on low or high expression of ZNF385B in patient primary tumors. The log rank p-value denoting statistical significance of difference in recurrence-free survival when comparing the two groups, as well as hazard ratio for this comparison is listed above. Listed below is the number of patients at risk (number of patients alive) per interval, after stratification based on ZNF385B expression; in the first interval, number at risk is number of patients alive; in each subsequent interval, number at risk is the number at risk less those who have expired or are censored.

1 Low ZNF385B expression: 17.76 months

2 High ZNF385B expression: 30.42 months

3
4 **Chart 2: Median recurrence-free survival is superior in basal subtype breast cancer patients with high primary tumor expression of ZNF385B.**

5 The median RFS (recurrence-free survival) of basal subtype breast cancer patients, with low primary
6 tumor expression of ZNF385B and high primary tumor expression of ZNF385B is listed in this chart.